Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
448 participants
INTERVENTIONAL
2008-02-29
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.
NCT01705184
Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
NCT00458315
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma
NCT00142467
Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC
NCT00517595
Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma
NCT01211275
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Standard Chemotherapy
Standard Chemotherapy (Pemetrexed and Cisplatin)
* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)
* Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)
2
Standard Chemotherapy + bevacizumab (Avastin)
Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)
* Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)
* Bevacizumab 15 mg/kg D1 (D1=D22, until progression)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard Chemotherapy (Pemetrexed and Cisplatin)
* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)
* Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)
Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)
* Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)
* Bevacizumab 15 mg/kg D1 (D1=D22, until progression)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In case of pleural effusion, a talc pleurodesis, although not recommended, is allowed in accordance with current local practice, at the time of diagnostic thorascopy, with inclusion CT scan performed after pleurodesis.
* ECOG Performance status 0-2
* Mesothelioma with only pleural effusion without uni- or bidimensionally measurable disease will be eligible (adapted RECIST criteria)
* At least 18 years of age, less than 76 years of age
* Radiation therapy of thoracocentis tract (3 x 7Gy) performed before beginning medical study treatment, and the interval between thoracoscopic procedure and radiation will not exceed 28 days
Exclusion Criteria
* Brain metastasis
* History of cerebral vascular accident (CVA) or transient ischemic attack
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Caen
OTHER
Groupe Francais De Pneumo-Cancerologie
OTHER
Intergroupe Francophone de Cancerologie Thoracique
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilles Robinet, Dr
Role: STUDY_DIRECTOR
GFPC
Arnaud Scherpereel, Dr
Role: STUDY_DIRECTOR
Intergroupe Francophone de Cancerologie Thoracique
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier du Pays d'Aix
Aix-en-Provence, , France
Annemasse - CH
Ambilly, , France
Amiens - CHU
Amiens, , France
Clinique de l'Europe
Amiens, , France
Angers - CHU
Angers, , France
Auxerre - CH
Auxerre, , France
CHU Besancon - Pneumologie
Besançon, , France
Béziers - CH
Béziers, , France
Bobigny - Hôpital Avicenne
Bobigny, , France
Bois-Guillaume - CHU
Bois-Guillaume, , France
Boujan sur Libron - Polyclinique Saint-Privat
Boujan-sur-Libron, , France
Hôpital Ambroise Paré - Pneumologie
Boulogne, , France
Brest - CHU
Brest, , France
Brest - HIA
Brest, , France
Caen - Centre François Baclesse
Caen, , France
CHU - Pneumologie
Caen, , France
Chauny - CH
Chauny, , France
Cherbourg - CH
Cherbourg, , France
Hôpital Percy-Armées - Pneumologie
Clamart, , France
CHU
Clermont-Ferrand, , France
Colmar - CH
Colmar, , France
Créteil - CHI
Créteil, , France
Denain - CH
Denain, , France
Centre Georges François Leclerc
Dijon, , France
CHU Hôpital du Bocage
Dijon, , France
Elbeuf - CH
Elbeuf, , France
Evreux - CH
Évreux, , France
Flers - CH
Flers, , France
CHU Grenoble - pneumologie
Grenoble, , France
Chartres - CH
Le Coudray, , France
Centre Hospitalier - Pneumologie
Le Havre, , France
Le Havre - HPE
Le Havre, , France
Centre Hospitalier - Pneumologie
Le Mans, , France
Le Mans - Clinique Victor Hugo
Le Mans, , France
CHU (Hôpital Calmette) - Pneumologie
Lille, , France
Limoges - Hôpital du Cluzeau
Limoges, , France
CH de Longjumeau
Longjumeau, , France
Lorient - CHBS
Lorient, , France
Centre Léon Bérard
Lyon, , France
HCL - Croix-Rousse
Lyon, , France
APHM - Hôpital Sainte Marguerite
Marseille, , France
Meaux - CH
Meaux, , France
Mont de Marsan - CH
Mont-de-Marsan, , France
Montpellier - CHRU
Montpellier, , France
Mulhouse - CH
Mulhouse, , France
CHU
Nancy, , France
Nantes - Centre René Gauducheau
Nantes, , France
Narbonne - Polyclinique Le Languedoc
Narbonne, , France
Nevers - CH
Nevers, , France
Nice - CAC
Nice, , France
Orléans - CH
Orléans, , France
Paray Le Monial - CH
Paray-le-Monial, , France
Paray Le Monial - Clinique
Paray-le-Monial, , France
Paris - Saint Louis
Paris, , France
APHP - Hopital Tenon - Pneumologie
Paris, , France
Paris - Curie
Paris, , France
Pau - CH
Pau, , France
HCL - Lyon Sud (Pneumologie)
Pierre-Bénite, , France
CHU
Poitiers, , France
Pontoise - CH
Pontoise, , France
Reims - CHU
Reims, , France
Rennes - CHU
Rennes, , France
Roubaix - CH
Roubaix, , France
Rouen - CHU
Rouen, , France
Saint Brieuc - CHG
Saint-Brieuc, , France
Centre Etienne Dolet
Saint-Nazaire, , France
Saint-Nazaire - CH
Saint-Nazaire, , France
Institut de Cancérologie de la Loire
Saint-Priest-en-Jarez, , France
Saint Quentin - CH
Saint-Quentin, , France
Saint-Malo - CH
St-Malo, , France
Strasbourg - NHC
Strasbourg, , France
Suresnes - Hopital Foch
Suresnes, , France
Thonon les bains - CH
Thonon-les-Bains, , France
Toulon - CHI
Toulon, , France
CHU Toulouse - Pneumologie
Toulouse, , France
Tours - CHU
Tours, , France
CH Valence
Valence, , France
Valenciennes - Clinique
Valenciennes, , France
CHI de la Haute-Saône - Pneumologie
Vesoul, , France
CH de Villefranche - Pneumologie
Villefranche, , France
Institut Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Riviere F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405-1414. doi: 10.1016/S0140-6736(15)01238-6. Epub 2015 Dec 21.
Levallet G, Dubois F, Elie N, Creveuil C, Brosseau S, Danel C, Scherpereel A, Lantuejoul S, Mazieres J, Greillier L, Audigier-Valette C, Bergot E, Moro-Sibilot D, Molinier O, Lena H, Monnet I, Morin F, Gounant V, Zalcman G. VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial. Lung Cancer. 2023 Aug;182:107287. doi: 10.1016/j.lungcan.2023.107287. Epub 2023 Jun 26.
Brosseau S, Danel C, Scherpereel A, Mazieres J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. Clin Lung Cancer. 2019 Sep;20(5):e564-e575. doi: 10.1016/j.cllc.2019.04.010. Epub 2019 May 13.
Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Muller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J; SOLE Investigators. Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. Br J Cancer. 2019 May;120(10):959-967. doi: 10.1038/s41416-019-0435-4. Epub 2019 Apr 10.
Related Links
Access external resources that provide additional context or updates about the study.
Official website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IFCT-GFPC-0701
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.